Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    S4 Capital

    MCap

    GBP137m

    Last close

    GBP0.20

    ▲ 3.90 (23.64%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Filtronic

    MCap

    GBP388m

    Last close

    GBP1.76

    ▲ 26.00 (17.33%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Bull, Bear & Beyond – Actinogen Medical: executive interview

Bull, Bear & Beyond – Actinogen Medical: executive interview

Actinogen Medical — 1 video in collection

More on this equity

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and selective 11β-HSD1 inhibitor designed to prevent excess cortisol production in the brain and thereby reduce the progression of chronic neurodegenerative conditions such as Alzheimer’s disease (AD). Xanamem has also shown therapeutic activity in the treatment of major depressive disorder.

Listen on your preferred podcast player below:

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.

< Previous
Next >

You may also be interested in these:

Healthcare

Bull, Bear & Beyond – Herantis Pharma: executive interview

Healthcare

Bull, Bear & Beyond – Mendus: executive interview